Vinay Patel, MD
Endocrinology, Diabetes & Metabolism · Neenah, WINPI 1477764744
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,281 of the $63,746 with a category attached, or 75.7%. Novo Nordisk accounts for 78.7% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $20,480 and has fallen 90.3% since, to $1,979 in 2025. Among endocrinology, diabetes & metabolism clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $140.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$50K
- Johnson & Johnson$8K
- Medtronic$2K
- AstraZeneca$632
- Sanofi-aventis U.S. LLC$603
- Lilly USA, LLC$464
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$48,28176%
- Travel & lodging$7,50612%
- Food & beverage$7,65312%
- Education$3060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 232 | $50,172 |
| Johnson & Johnson | 32 | $8,146 |
| Medtronic(2 entities) | 24 | $1,913 |
| AstraZeneca | 35 | $632 |
| Sanofi-aventis U.S. LLC | 19 | $603 |
| Lilly USA, LLC | 31 | $464 |
| Boehringer Ingelheim | 20 | $308 |
| Abbott | 8 | $199 |
| Insulet Corporation | 9 | $195 |
| Bayer | 2 | $160 |
| Tandem Diabetes Care, Inc. | 8 | $149 |
| Kyowa Kirin, Inc. | 1 | $121 |
| Merck | 7 | $93 |
| Amgen | 6 | $93 |
| Dexcom, Inc. | 5 | $91 |
| Sanofi | 2 | $85 |
| Ascensia Diabetes Care US Inc. | 2 | $75 |
| AbbVie | 3 | $47 |
| Novartis | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $39 |
| C2dx, Inc | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$39,684
- INVOKANA$7,727
- Saxenda$6,899
- Minimed 670G System$1,516
- SOLIQUA 100/33$350
- RYBELSUS$225
- Ozempic$204
- Tresiba$103
How this compares
$63,746 in reported general payments places this provider in the 90th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 261 | $435,145 |
| MounjaroTirzepatide | 95 | $159,236 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 115 | $138,720 |
| JardianceEmpagliflozin | 74 | $79,121 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $69,010 |
| TrulicityDulaglutide | 36 | $59,047 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 33 | $51,582 |
| RybelsusSemaglutide | 35 | $49,328 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 23 | $37,169 |
| FarxigaDapagliflozin Propanediol | 27 | $32,846 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $29,404 |
| JanuviaSitagliptin Phosphate | 26 | $21,052 |
| Cinacalcet Hcl | 13 | $11,382 |
| Novolog FlexpenInsulin Aspart | 37 | $11,195 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $50,172 | $489,083307 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $464 | $224,825145 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr | $308 | $167,872130 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $603 | $138,720115 claims |
| AstraZenecaFarxiga | $632 | $32,84627 claims |
| MerckJanuvia | $93 | $21,05226 claims |
| AbbVieSynthroid | $47 | $9,01972 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Neenah
- John MihailidisNeenah$378
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.